Michelle Petri, MD
Rheumatology · Baltimore, MDNPI 1548206683
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $266,157 of the $380,959 with a category attached, or 69.9%. 30 manufacturers reported payments, led by AstraZeneca at 24.3% of the total. Among rheumatology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $1454.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$93K
- GSK$84K
- Aurinia Pharma U.S., Inc.$49K
- Eli Lilly$37K
- Sanofi-aventis U.S. LLC$29K
- UCB SA$15K
- plus $74K from 24 others
Across 39 payments — averaging $17,919 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$417K
- Janssen Global Services, LLC$105K
- Astrazeneca UK Limited$90K
- Merck$64K
- EMD Serono Research & Development Institute, Inc.$9K
- AbbVie$4K
- plus $10K from 6 others
What the payments were for
- Consulting fees$266,15770%
- Speaking & faculty fees$80,51021%
- Travel & lodging$32,1388%
- Food & beverage$2,1541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 40 | $92,739 |
| GSK | 61 | $84,039 |
| Aurinia Pharma U.S., Inc. | 33 | $49,072 |
| Eli Lilly | 33 | $36,602 |
| Sanofi-aventis U.S. LLC | 7 | $29,217 |
| UCB SA | 6 | $14,910 |
| Amgen | 14 | $9,336 |
| Janssen Research & Development, LLC | 7 | $9,330 |
| Merck | 6 | $7,048 |
| E.r. Squibb & Sons, L.L.C. | 4 | $6,725 |
| EMD Serono Research & Development Institute, Inc. | 4 | $5,125 |
| Regeneron | 5 | $4,428 |
| Biogen | 3 | $4,187 |
| UCB, Inc. | 1 | $3,540 |
| EMD Serono, Inc. | 2 | $3,000 |
| Sanofi US Services Inc. | 1 | $2,720 |
| Emergent Biosolutions Inc. | 4 | $2,610 |
| Autolus Inc | 3 | $2,591 |
| AbbVie | 9 | $2,143 |
| Astrazeneca UK Limited | 1 | $2,014 |
| Phadia GmbH | 2 | $1,940 |
| Inova Diagnostics, Inc. | 1 | $1,400 |
| Astellas Pharma Inc | 2 | $1,288 |
| Bavarian Nordic A/s | 2 | $990 |
| UCB GmbH | 1 | $900 |
| Novartis | 5 | $884 |
| Boehringer Ingelheim | 2 | $645 |
| Biocryst Pharmaceuticals, Inc. | 1 | $595 |
| Orphai Therapeutics Inc. | 1 | $500 |
| Vertex | 1 | $442 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$380,959 in reported general payments places this provider in the 95th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BenlystaBelimumab | 11 | $53,268 |
| Hydroxychloroquine Sulfate | 518 | $32,275 |
| FarxigaDapagliflozin Propanediol | 19 | $23,229 |
| Mycophenolate Mofetil | 56 | $13,541 |
| RasuvoMethotrexate/Pf | 11 | $9,873 |
| Azathioprine | 20 | $2,579 |
| MethotrexateMethotrexate Sodium | 63 | $1,820 |
| Metoprolol Succinate | 75 | $1,774 |
| Famotidine | 60 | $1,233 |
| Duloxetine Hcl | 28 | $1,173 |
| Enalapril Maleate | 34 | $1,091 |
| Atorvastatin Calcium | 65 | $1,009 |
| Amitriptyline Hcl | 47 | $901 |
| Losartan Potassium | 67 | $872 |
| Prednisone | 80 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBenlysta | $84,039 | $53,26811 claims |
| AstraZenecaFarxiga | $92,739 | $23,22919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 173 rheumatology providers in Maryland.
Other rheumatology in Baltimore
- Marc HochbergBaltimore$124K
- Clifton BinghamBaltimore$117K
- Lisa ChristopherBaltimore$92K
- Philip SeoBaltimore$84K
- Laura HummersBaltimore$80K
- Rachel WallworkBaltimore$71K
- Thomas Grader BeckBaltimore$55K
- Andrea FavaBaltimore$38K
- Christopher MecoliBaltimore$34K
- Laura CappelliBaltimore$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.